Review



halogenated spirooxindole  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals halogenated spirooxindole
    Architecture of kinase's catalytic domain and molecular aspects of <t>spirooxindole</t> scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.
    Halogenated Spirooxindole, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/halogenated spirooxindole/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    halogenated spirooxindole - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach"

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    Journal: RSC Advances

    doi: 10.1039/d5ra03404c

    Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.
    Figure Legend Snippet: Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.

    Techniques Used: Binding Assay

    Synthesis of spirooxindole 16.
    Figure Legend Snippet: Synthesis of spirooxindole 16.

    Techniques Used:

    Synthetic routes of spirooxindole derivatives (21a–l).
    Figure Legend Snippet: Synthetic routes of spirooxindole derivatives (21a–l).

    Techniques Used:

    Synthesis of di-spirooxindole derivatives (25a–n).
    Figure Legend Snippet: Synthesis of di-spirooxindole derivatives (25a–n).

    Techniques Used:

    Synthesis of spirooxindole derivatives (28a–m).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (28a–m).

    Techniques Used:

    Synthesis of spirooxindole derivatives (37a–g).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (37a–g).

    Techniques Used:

    Synthesis of spirooxindole derivatives (40a–c).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (40a–c).

    Techniques Used:

    Synthesis of spirooxindole derivatives (43a–o).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (43a–o).

    Techniques Used:

    Synthesis of spirooxindole derivatives (45a–o).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (45a–o).

    Techniques Used:

    Synthesis of spirooxindole derivatives 48a–l.
    Figure Legend Snippet: Synthesis of spirooxindole derivatives 48a–l.

    Techniques Used:

    Synthesis of spirooxindole derivatives (8a–h).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (8a–h).

    Techniques Used:

    Synthesis of bi-spirooxindole derivatives 54a–o.
    Figure Legend Snippet: Synthesis of bi-spirooxindole derivatives 54a–o.

    Techniques Used:

    Synthesis of spirooxindole derivatives (60a–i).
    Figure Legend Snippet: Synthesis of spirooxindole derivatives (60a–i).

    Techniques Used:



    Similar Products

    halogenated spirooxindole  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals halogenated spirooxindole
    Architecture of kinase's catalytic domain and molecular aspects of <t>spirooxindole</t> scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.
    Halogenated Spirooxindole, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/halogenated spirooxindole/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    halogenated spirooxindole - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Architecture of kinase's catalytic domain and molecular aspects of spirooxindole scaffold binding at the ATP canonical binding site. (A) Cartoon/surface 3D-representation of the conserved folded tertiary architecture of an example kinase biotarget; CDK2 (PDB_ID: 1qmz ) in complex with ATP molecule (orange sticks), Mg +2 ion (green sphere) and protein substrate (cartoon). Key kinase structural motifs and secondary structures are color-coded. The amino and carboxy-termini are denoted with letters N and C, respectively; (B) Detailed ATP-binding site showing the four main sub-pockets (①–④) for the recognition and binding to main scaffolds of the small molecule kinase inhibitors: (C) key pharmacophoric features of reported small molecule kinase inhibitors and the quite superimposition of the spirooxindole scaffolds over these features. Pharmacophoric features are shown in the 3D-spatial arrangement of color-coded meshed spheres (purple = hydrogen bond acceptor HAcc; blue = hydrogen bond donor HDo, and orange = aromatic rings Aro). Arrows denote the projection/directionality of the hydrogen bonds.

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques: Binding Assay

    Synthesis of spirooxindole 16.

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole 16.

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthetic routes of spirooxindole derivatives (21a–l).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthetic routes of spirooxindole derivatives (21a–l).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of di-spirooxindole derivatives (25a–n).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of di-spirooxindole derivatives (25a–n).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (28a–m).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (28a–m).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (37a–g).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (37a–g).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (40a–c).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (40a–c).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (43a–o).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (43a–o).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (45a–o).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (45a–o).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives 48a–l.

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives 48a–l.

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (8a–h).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (8a–h).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of bi-spirooxindole derivatives 54a–o.

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of bi-spirooxindole derivatives 54a–o.

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques:

    Synthesis of spirooxindole derivatives (60a–i).

    Journal: RSC Advances

    Article Title: Recent advances in the halogenated spirooxindoles as novel anticancer scaffolds: chemistry and bioactivity approach

    doi: 10.1039/d5ra03404c

    Figure Lengend Snippet: Synthesis of spirooxindole derivatives (60a–i).

    Article Snippet: This makes halogenated spirooxindole very promising as a potential anticancer agent, either as a multitarget or selective kinase inhibitor.

    Techniques: